PPD (NASDAQ:PPD) Releases Q1 2021 After-Hours Earnings Guidance

PPD (NASDAQ:PPD) updated its first quarter 2021
After-Hours earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.30-0.32 for the period, compared to the Thomson Reuters consensus estimate of $0.32. The company issued revenue guidance of $1.277-1.302 billion, compared to the consensus revenue estimate of $1.23 billion.PPD also updated its FY 2021
After-Hours guidance to 1.37-1.45 EPS.

A number of research firms have commented on PPD. Deutsche Bank Aktiengesellschaft lifted their target price on shares of PPD from $33.00 to $38.00 and gave the stock a buy rating in a report on Thursday, October 29th. Zacks Investment Research raised shares of PPD from a hold rating to a buy rating and set a $39.00 price target on the stock in a research report on Tuesday, November 17th. Seventeen equities research analysts have rated the stock with a buy rating, PPD has a consensus rating of Buy and an average price target of $35.06.

PPD traded down $0.25 during trading on Tuesday, hitting $36.33. The company had a trading volume of 935,152 shares, compared to its average volume of 864,004. The company has a market capitalization of $12.70 billion and a PE ratio of 238.07. PPD has a one year low of $10.61 and a one year high of $38.76. The firm’s 50-day moving average price is $35.68 and its 200 day moving average price is $34.61.

In other PPD news, CEO David S. Simmons sold 77,065 shares of PPD stock in a transaction on Friday, February 12th. The shares were sold at an average price of $38.01, for a total value of $2,929,240.65. Following the sale, the chief executive officer now directly owns 669,999 shares in the company, valued at approximately $25,466,661.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

About PPD

PPD, Inc provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services.

Read More: What are the reasons investors use put options?

Earnings History and Estimates for PPD (NASDAQ:PPD)

Receive News & Ratings for PPD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPD and related companies with MarketBeat.com's FREE daily email newsletter.